

The Immunological Basis for Immunization Series

Module 12: pneumococcal vaccines

Immunization, Vaccines and Biologicals



**World Health
Organization**

The Immunological Basis for Immunization Series

Module 12:
pneumococcal vaccines

Immunization, Vaccines and Biologicals



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

The immunological basis for immunization series : module 12: pneumococcal vaccines / Helena Käyhty ... [et al].

(Immunological basis for immunization series ; module 12)

1.Streptococcus pneumoniae - immunology. 2.Streptococcus pneumoniae - pathogenicity. 3.Pneumococcal infections - immunology.
4.Vaccines, Conjugate - standards. I.Käyhty, Helena. II.Nurkka, Anu. III.Soininen, Anu. IV.Väkeväinen, Merja. V.World Health Organization. VI.Series.

ISBN 978 92 4 159821 7

(NLM classification: WC 204)

© World Health Organization 2009

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

**The Department of Immunization, Vaccines and Biologicals
thanks the donors whose unspecified financial support
has made the production of this document possible.**

This module was produced for Immunization, Vaccines and Biologicals, WHO, by:

Authors: Helena Käyhty, Ph.D; Anu Nurkka, Ph.D;
Anu Soininen, Ph.D; Merja Väkeväinen, Ph.D
Department of Vaccination and Immune Protection,
National Institute of Health and Welfare,
P.O. Box 30, 00271 Helsinki, Finland

The authors would like to thank
Dr David Goldblatt and Dr Carl Frasch, who reviewed the document.

Printed in September 2009

**Copies of this publications as well as additional materials
on immunization, vaccines and biological may be requested from:**

World Health Organization
Department of Immunization, Vaccines and Biologicals
CH-1211 Geneva 27, Switzerland
• *Fax:* + 41 22 791 4227 • *Email:* vaccines@who.int •

© World Health Organization 2009

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

<i>Abbreviations and acronyms</i>	<i>v</i>
<i>Preface</i>	<i>vii</i>
1. The organism and the disease	1
2. Pneumococcal vaccines	3
3. Measurement of immunity	5
3.1 <i>Quantitation of antibodies</i>	5
3.2 <i>Functional assays (OPA)</i>	7
3.3 <i>Assessment of antibody avidity</i>	8
3.4 <i>Assessment of cell-mediated immunity</i>	9
3.5 <i>Assessment of immunological memory</i>	9
4. Immunological response to natural infection	10
4.1 <i>Host defence mechanisms</i>	10
4.2 <i>Development of immunity</i>	10
5. Response to vaccination	12
5.1 <i>Polysaccharide vaccine</i>	12
5.2 <i>Conjugate vaccines</i>	13
6. Serological correlates for protection	25
7. Vaccine effectiveness	27
8. Future prospects	29
References	30

Abbreviations and acronyms

AOM	acute otitis media
aP	acellular pertussis vaccine
CAP	community-acquired pneumonia
CI	confidence interval
C-PS	cell wall polysaccharide
CRM	nontoxic variant diphtheria toxin
DT	diphtheria toxoid
DTP	diphtheria, tetanus and pertussis combination vaccine
EIA	enzyme immunoassay
ELISPOT	enzyme linked immunospot assay
EPI	Expanded Programme on Immunization
FinOM	Finnish Otitis Media Vaccine Trial
GMC	geometric mean concentration
Hib	<i>Haemophilus influenzae</i> type b
HIV	human immunodeficiency virus
Ig	immunoglobulin, e.g. IgA, IgG, IgM
IPD	invasive pneumococcal disease
IPV	inactivated poliovirus vaccine
K	constant value
LXA	Luminex multiple analyte
MCV-C-CRM	meningococcal group C conjugate vaccine using CRM carrier
MMR	measles, mumps and rubella combination vaccine
NCKP	Northern California Kaiser Permanente
NVT	non-vaccine serotype
OMPC	outer membrane protein complex
OPA	opsonophagocytosis assay
PCV	pneumococcal conjugate vaccine
PCV7-CRM	7-valent PCV using CRM carrier
PCV9-CRM	9-valent PCV using CRM carrier

PCV7-OMPC	7-valent PCV using meningococcal OMPC carrier
PCV11-PD	11-valent PCV using <i>H. influenzae</i> protein D carrier
PCV4-T	4-valent PCV using TT carrier
PCV11-D-T	11-valent mixed carrier PCV using both DT and TT carrier
PD	protein D of <i>H. Influenzae</i>
POET	PCV11-PD efficacy trial conducted in Czeck Republic and Slovakia
PPSV	pneumococcal polysaccharide vaccine
PRP-CRM	Hib conjugate vaccine using CRM carrier
PRP-T	Hib conjugate vaccine using TT carrier
PS	polysaccharide
RIA	radio immunoassay
TT	tetanus toxoid
USA	the United States of America
VT	vaccine serotype
wP	whole cell pertussis vaccine
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29281

